JPRN-jRCT1090220258
Recruiting
未知
Clinical effects of everolimus in the ubjects with tuberous sclerosis. - Clinical effects of everolimus in the subjects with ASD
Kunio Yui0 sites20 target enrollmentAugust 2, 2016
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- there are a few individuals with TSC with SEGA who exhibite ASD symptoms.
- Sponsor
- Kunio Yui
- Enrollment
- 20
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Individuals with autism spectrum disorders in TSC
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Efficacy and Safety of Everolimus in Patients with Unresectable or Metastatic Renal Cell Carcinomarenal cell carcinomaJPRN-UMIN000008769Tokyo Afinitor Clinical Trial Group - RCC(TACT-R)120
Not yet recruiting
Phase 2
Efficacy and Safety of Everolimus in Patients with Non-Clear Cell Renal Cell Carcinomaon-clear cell renal cell carcinomaJPRN-UMIN000006248Yamaguchi University Graduate School of Medicine , Department of Urology10
Active, not recruiting
Phase 1
Introduction of everolimus is associated with a reduction in the dosage of calcineurine-inhibitors in patients with a pulmonary graft who suffer from a notable chronic renal insuffisance.Patient who received a pulmonary transplant and who show notable renale insuffisance (DFG < 50ml/min/1.73m²) which has been progressive over the last two years or chronical renal insuffisance which progresses fast (a los of >50% DGF in 3 months) and isotopical glomerural filtration < 45 ml/min.EUCTR2006-001945-32-BEB Erasme15
Recruiting
Phase 2
Efficacy of 0.05%topical everolimus in the treatment of adenoma sebaceum in tuberous sclerosisadenoma sebaceumTCTR20180820002Dermatology division, Department of internal medicine, King Chulalongkorn Memorial Hospital15
Not yet recruiting
Not Applicable
In-vivo Bioequivalence Test of NEORAPA® tablet with brand drugs (AFINITOR® 10mg Novartis).In this study, the disease is not examined. Subject bioequivalence test and reference tablets Everolimus studied..IRCT20200105046010N24ABIDI Pharmaceutical Company24